Filter Results:
(1,329)
Show Results For
- All HBS Web
(1,329)
- People (1)
- News (333)
- Research (819)
- Events (1)
- Multimedia (8)
- Faculty Publications (593)
Show Results For
- All HBS Web
(1,329)
- People (1)
- News (333)
- Research (819)
- Events (1)
- Multimedia (8)
- Faculty Publications (593)
- Career Coach
Kaitlin Hearn
Kaitlin grew up in Canada and studied engineering, but has spent the bulk of her career in finance and consulting in New York. As a serial career switcher herself, Kaitlin is well positioned to help you think through the merits and... View Details
- Summer 2023
- Article
Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?
By: Eric Barrette, Leemore S. Dafny and Karen Shen
Even among commercially insured individuals, opioid use disorder is undertreated in the United States: nearly half receive no treatment within six months of a new diagnosis. Using a difference-in-differences specification exploiting the extension of insurance parity... View Details
Keywords: Opioid Treatment; Medication-assisted Treatment; Substance Use Disorder; Private Insurance; Insurance; Health Care and Treatment
Barrette, Eric, Leemore S. Dafny, and Karen Shen. "Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?" American Journal of Health Economics 9, no. 3 (Summer 2023): 297–330.
- September 2022
- Article
Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities
By: Leemore Dafny, Christopher Ody and Teresa Rokos
The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations... View Details
Keywords: Cost Sharing; Prescription Drugs; Drug Spending; Medicare; Dual Eligibility; Cost; Health Care and Treatment; Philanthropy and Charitable Giving; Pharmaceutical Industry
Dafny, Leemore, Christopher Ody, and Teresa Rokos. "Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities." Health Affairs 41, no. 9 (September 2022).
- Fast Answer
Student Proposed Fellowship Program - Resources for selecting your organization
The following resources can be used to identify nonprofit organizations: Identifying Organizations Search Strategies GuideStar Pro - Information about the missions, programs, and finances of more than 1.7 million nonprofit... View Details
- 01 Dec 2004
- News
Finding a Balance
political issues for students, so it fits well with the LCA curriculum.” Cipla’s CEO, Dr. Yusef Hamied, figures prominently in the case. A Cambridge University–educated chemist, Hamied is revered by some for his humanitarian projects (including several View Details
- Article
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
- Web
Student Clubs | MBA
Family Business Club Finance Club FinTech Club First Generation Students Club Food and Agriculture Club Football/Soccer Club Formula One Club French-Speaking Club Future of Mobility Future of Work Club G Gaming and Game Industry Club... View Details
- August 2024
- Article
How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
Keywords: Prescription Drugs; Coupons; Impact; Health Care and Treatment; Markets; Price; Spending; Pharmaceutical Industry; United States
Dafny, Leemore S., Kate Ho, and Edward Kong. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?" American Economic Journal: Economic Policy 16, no. 3 (August 2024): 314–346.
- Web
Courses by Title - Course Catalog
Management Robert Simons Fall 2025 Q1Q2 3.0 The Coming of Managerial Capitalism Entrepreneurial Management Tom Nicholas Spring 2026 Q3Q4 3.0 Corporate Finance: Corporate Financial Operations (CFO) Finance C. Fritz Foley Fall 2025 Q1Q2 3.0... View Details
- 08 Mar 2017
- News
A Steady Voice in Difficult Times
Denise Welsh (MBA 1981) is a pediatric chaplain at Mount Sinai Medical Center, a second career after having spent many years in the finance field. In this video, she talks about her role in the intensive care unit and the impact of... View Details
- 30 Apr 2001
- What Do You Think?
Dot.Com Shakeout: Chess or Roulette?
was that of T. N. Rao: "There is an immense business opportunity now for all the investing companies to pick up some very good dot.coms that have very sound business models. It is just that the principles of assessing the health of... View Details
Keywords: by James Heskett
- 18 Feb 2016
- Blog Post
Honing an Interest in Healthcare at HBS
internship with a well-known healthcare expert organization to do some consulting work. I also took a class in health policy over at the Kennedy School, and spent quite a bit of time in and out of class with a small core of students from... View Details
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details
Keywords: Gene Therapy; Gene Editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change
Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
- 01 Dec 2004
- News
Boom Times Ahead
half of next year.” Dent said that the four sectors that represent the best investments are technology, financial services, health care, and Asia. And don’t delay — according to Dent, the boom will end in 2009. View Details
- August 2025
- Article
Revenue Collapses and the Consumption of Small Business Owners in the COVID-19 Pandemic
By: Olivia S. Kim, Jonathan A. Parker and Antoinette Schoar
Using financial account data linking small businesses to their owner households, we examine how business owners’ consumption responded to changes in business revenues during the COVID-19 crisis. In the first two months following the National Emergency, business... View Details
Kim, Olivia S., Jonathan A. Parker, and Antoinette Schoar. "Revenue Collapses and the Consumption of Small Business Owners in the COVID-19 Pandemic." Art. 104079. Journal of Financial Economics 170 (August 2025).
- 09 Jun 2020
- Working Paper Summaries
Aggregate and Firm-Level Stock Returns During Pandemics, in Real Time
- Web
Derek Soled Archives | Social Enterprise
Impact Measurement Inclusive Finance International Development K-12 Education Leadership Fellows Leadership in Challenging Times MBA Programs Microfinance Non Profit Management Nonprofit Supportive Services Public Sector Public-Private... View Details
- July 2002 (Revised December 2002)
- Case
Phase Two: The Pharmaceutical Industry Responds to AIDS
By: Debora L. Spar
Describes how major pharmaceutical firms changed their strategy and pricing policies in the years 2000 to 2002 to respond to the growing AIDS epidemic in Africa. View Details
Keywords: International Finance; Health Pandemics; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Africa
Spar, Debora L., and Nick Bartlett. "Phase Two: The Pharmaceutical Industry Responds to AIDS." Harvard Business School Case 703-005, July 2002. (Revised December 2002.)
- Profile
Zayed Muhammed Yasin
gives me the ability to mobilize and organize resources to address the big health problems among people who need the most help," he says. "If you understand finances and operations, you can find... View Details
- 13 Dec 2016
- First Look
December 13, 2016
fundamental firm value, which is gradually revealed into prices. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=51971 December 2016 Harvard Business Review Health Care Needs Real Competition By: Dafny, Leemore S., and... View Details
Keywords: Carmen Nobel